ISR News and Press, IsoRay Inc. From 09/28/22

IsoRay press release ( NYSE: ISR ): FQ4 GAAP EPS of -$0.01 in-line. Revenue of $2.51M (-7.4% Y/Y) misses by $0.33M . Cash, cash equivalents, and certificates of deposit at the end of the fiscal year ended June 30, 2022 totaled $55.9 million and the company had no l...

RICHLAND, Wash., Sept. 28, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it has entered into a definitive agreement to acquire Viewpoint Molecular Targeting, Inc. (Viewpoint) a precision...

IsoRay ( NYSE: ISR ) is scheduled to announce Q4 earnings results on Wednesday, September 28th, after market close. The consensus EPS Estimate is -$0.01 (flat Y/Y) and the consensus Revenue Estimate is $2.84M (+4.8% Y/Y). Over the last 3 months, EPS estimates have seen...

RICHLAND, Wash., Sept. 21, 2022 (GLOBE NEWSWIRE) -- Isoray , Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the fourth quarter and fiscal year ended...

RICHLAND, Wash., June 21, 2022 (GLOBE NEWSWIRE) -- The growing body of information regarding Iso r ay , Inc. ’s (NYSE American: ISR) Cesium-131 in treating prostate cancer was highlighted in two presentations at the just concluded American Brachytherapy Society’...

RICHLAND, Wash., June 15, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a lunch symposium featuring Dr. Stephen J. Frank of the MD Anderson Cancer Center at the American Bra...

Start Time: 16:30 End Time: 17:00 Isoray, Inc. (ISR) Q3 2022 Earnings Conference Call May 10, 2022, 16:30 PM ET Company Participants Lori Woods - CEO Jonathan Hunt - CFO Mark Levin - IR Conference Call Participants Frank Takkinen - Lake Street Capital Markets Mike Ott - Oppenheimer Tim Chiang...

IsoRay press release (NYSE:ISR): Q3 GAAP EPS of -$0.01 in-line. Revenue of $2.91M (+11.9% Y/Y) misses by $0.09M. Shares +3%. For further details see: IsoRay GAAP EPS of -$0.01 in-line, revenue of $2.91M misses by $0.09M

Revenue Increased 12% Year-Over-Year Record Non-Prostate Brachytherapy Revenue Increased 28% Year-Over-Year RICHLAND, Wash., May 10, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announce...

RICHLAND, Wash., April 29, 2022 (GLOBE NEWSWIRE) -- Isoray, Inc. (NYSE AMERICAN: ISR), a medical technology company and innovator in seed brachytherapy, today announced that it will host a conference call to discuss its financial results for the third quarter fiscal 2022 ended March 31,...